Weight loss is associated with improved quality of life in some, but not all, 
weight loss trials. We evaluated changes at 56 weeks in quality of life, 
measured by the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) 
questionnaire, in a pooled analysis of patient-level data from four randomized 
controlled Phase 3 studies of naltrexone/bupropion (NB32 or Contrave®). The 
total number of subjects was 3362 (NB32 = 2043; placebo = 1319; mean body mass 
index = 36.3 kg m(2); mean age = 46). Improvements in IWQOL-Lite Total Score 
were greater in subjects treated with NB32 (11.9 points [SE 0.3]) vs. placebo 
(8.2 points [SE 0.3]; P < 0.001), corresponding to weight reductions of 7.0% (SE 
0.2) and 2.3% (SE 0.2), respectively. Greater improvements were also observed 
for NB32 vs. placebo on all five subscale scores of the IWQOL-Lite. Fifty per 
cent of NB32-treated subjects achieved clinically meaningful improvements in 
IWQOL-Lite Total Score vs. 32.3% of placebo-treated subjects (odds ratio, 95% 
confidence interval; 2.09, 1.79-2.44). Subjects losing the most weight (≥ 15% of 
baseline weight) experienced the greatest improvement in IWQOL-Lite Total Score 
(19.3 points [SE 0.7] for NB32 and 18.7 points [SE 1.3] for placebo; P = 0.624). 
Improved quality of life was associated with weight reduction and was achieved 
in more subjects treated with NB32 than placebo.